10-KPeriod: FY2019

BIOGEN INC. Annual Report, Year Ended Dec 31, 2019

Filed February 6, 2020For Securities:BIIB

Summary

Biogen Inc.'s 2019 10-K filing highlights a year of strategic growth and pipeline advancement, particularly in its core areas of Multiple Sclerosis (MS) and Spinal Muscular Atrophy (SMA). The company reported a 6.9% increase in total revenues to $14.38 billion, driven by strong performance in SPINRAZA and anti-CD20 therapeutic programs, alongside the initial launch of VUMERITY. Significant R&D investments and strategic acquisitions, such as Nightstar Therapeutics, underscore Biogen's commitment to addressing complex neurological diseases, including Alzheimer's disease (AD) with the potential pursuit of regulatory approval for aducanumab. The company also focused on capital allocation, authorizing substantial share repurchase programs totaling $10 billion. Despite facing ongoing competition and pricing pressures, Biogen demonstrated resilience, with a notable increase in diluted earnings per share and a strong cash position, positioning it for continued investment in its pipeline and potential future growth opportunities.

Financial Highlights

56 data points
Beta

Revenue

$14.38B

86.4% Gross Margin

Net Income

$5.89B

41.0% Net Margin

EPS (Diluted)

$31.42

Total Assets

$27.23B

Cash & Equivalents

$2.91B

Free Cash Flow

$6.56B

Financial Statements
Beta
Revenue$14.38B
Cost of Revenue$1.96B
Gross Profit$12.42B
SG&A Expenses$2.37B
Operating Expenses$7.34B
Operating Income$7.04B
Interest Expense$187.40M
Net Income$5.89B
EPS (Basic)$31.47
EPS (Diluted)$31.42
Shares Outstanding (Basic)187.10M
Shares Outstanding (Diluted)187.40M

Key Highlights

  • 1Total revenues increased by 6.9% to $14.38 billion, primarily driven by growth in SPINRAZA and anti-CD20 therapeutic programs, and the launch of VUMERITY.
  • 2Diluted earnings per share (EPS) increased by 45.6% to $31.42, reflecting strong revenue growth and a lower effective tax rate.
  • 3Significant strategic advancements were made in the Alzheimer's disease pipeline, with plans to pursue regulatory approval for aducanumab following a re-analysis of Phase 3 trial data.
  • 4Acquisition of Nightstar Therapeutics plc expanded Biogen's ophthalmology pipeline with gene therapy assets for inherited retinal disorders.
  • 5VUMERITY received FDA approval for Relapsing MS (RMS) and became available in the U.S., contributing to product revenues.
  • 6The company authorized significant share repurchase programs totaling $10 billion during 2019, demonstrating a commitment to returning capital to shareholders.
  • 7Biogen continued to invest heavily in R&D across its core and emerging growth areas, with key collaborations and pipeline developments noted in MS, SMA, ALS, and Parkinson's disease.

Frequently Asked Questions

Biogen's financial performance in 2019 was driven by a 6.9% increase in total revenues to $14.38 billion. This growth was primarily fueled by a 4.5% increase in product revenues, with notable contributions from SPINRAZA (up 21.6%) and the biosimilars business (up 35.4%). Revenues from anti-CD20 therapeutic programs also saw a significant increase of 15.7%, largely due to higher royalty revenues from OCREVUS. This top-line growth, combined with a decrease in total cost and expenses (down 3.0%) and a lower effective tax rate, led to a substantial increase in diluted earnings per share by 45.6% to $31.42.

In 2019, Biogen made significant strides in its pipeline. A major highlight was the decision to pursue regulatory approval in the U.S. for aducanumab for Alzheimer's disease, based on a new analysis of Phase 3 data. The company also strengthened its ophthalmology portfolio by acquiring Nightstar Therapeutics, adding gene therapy assets for inherited retinal disorders. Furthermore, VUMERITY received FDA approval for Relapsing MS, marking a new product launch. Biogen also expanded its early-stage research through collaborations, such as with Skyhawk Therapeutics for neurological diseases, and exercised an option to license BIIB080 (tau ASO) for Alzheimer's disease from Ionis Pharmaceuticals.

Biogen is actively managing competitive pressures and patent expirations through several strategies. The company is developing next-generation therapies for MS, aiming to reverse or repair disease damage. For TECFIDERA, while anticipating generic competition due to ongoing patent litigation and settlement agreements, Biogen expects volume growth in rest-of-world markets to offset U.S. declines in 2020. The company is also expanding its biosimilar business through its Samsung Bioepis joint venture, gaining rights to ophthalmology biosimilars. The risk factors section also highlights the company's reliance on its products and the potential impact of generics, biosimilars, and new competing products.